New Zealand markets closed

Jasper Therapeutics, Inc. (JSPR)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
29.90+1.08 (+3.73%)
As of 03:39PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close28.82
Open29.99
Bid29.45 x 100
Ask30.05 x 100
Day's range29.45 - 31.00
52-week range4.00 - 31.00
Volume74,617
Avg. volume132,205
Market cap450.335M
Beta (5Y monthly)2.18
PE ratio (TTM)N/A
EPS (TTM)-61.80
Earnings date10 May 2024 - 14 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est68.33
  • GlobeNewswire

    Jasper Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

    REDWOOD CITY, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced that its management will participate in a fireside chat at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

  • GlobeNewswire

    Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria

    REDWOOD CITY, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced that the first patient has been dosed in Jasper’s Phase 1b/2a (SPOTLIGHT) clinical study of subcutaneous briquilimab for the treatment of CIndU. The S

  • GlobeNewswire

    New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia

    Three additional patients with Fanconi Anemia treated with briquilimab prior to stem cell transplantAll six patients with Fanconi Anemia treated with briquilimab achieved full donor engraftment and full blood count recovery and briquilimab was well tolerated REDWOOD CITY, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell